sk&f-38393 has been researched along with Dyskinesia, Medication-Induced in 48 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol-induced VC were inhibited by the s." | 1.28 | Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. ( Collu, M; Diana, M; Gessa, GL; Mura, A, 1992) |
| "The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats." | 1.28 | Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. ( Lucki, I; McGonigle, P; Neisewander, JL, 1991) |
| "Treatment with haloperidol (0." | 1.28 | Drug-induced purposeless chewing: animal model of dyskinesia or nausea? ( Iversen, SD; Rupniak, NM; Tye, SJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (20.83) | 18.7374 |
| 1990's | 16 (33.33) | 18.2507 |
| 2000's | 12 (25.00) | 29.6817 |
| 2010's | 8 (16.67) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Kiessling, CY | 1 |
| Lanza, K | 1 |
| Feinberg, E | 1 |
| Bishop, C | 1 |
| Andreoli, L | 1 |
| Abbaszadeh, M | 1 |
| Cao, X | 1 |
| Cenci, MA | 2 |
| Arcuri, L | 1 |
| Novello, S | 1 |
| Frassineti, M | 1 |
| Mercatelli, D | 1 |
| Pisanò, CA | 1 |
| Morella, I | 1 |
| Fasano, S | 1 |
| Journigan, BV | 1 |
| Meyer, ME | 1 |
| Polgar, WE | 1 |
| Brambilla, R | 1 |
| Zaveri, NT | 1 |
| Morari, M | 1 |
| Suárez, LM | 1 |
| Solís, O | 1 |
| Caramés, JM | 1 |
| Taravini, IR | 1 |
| Solís, JM | 1 |
| Murer, MG | 1 |
| Moratalla, R | 1 |
| Iderberg, H | 1 |
| Rylander, D | 1 |
| Bimpisidis, Z | 1 |
| Farré, D | 1 |
| Muñoz, A | 2 |
| Moreno, E | 2 |
| Reyes-Resina, I | 1 |
| Canet-Pons, J | 1 |
| Dopeso-Reyes, IG | 1 |
| Rico, AJ | 1 |
| Lluís, C | 1 |
| Mallol, J | 1 |
| Navarro, G | 2 |
| Canela, EI | 1 |
| Cortés, A | 2 |
| Labandeira-García, JL | 2 |
| Casadó, V | 2 |
| Lanciego, JL | 2 |
| Franco, R | 2 |
| Casadó-Anguera, V | 1 |
| Petrovic, M | 1 |
| Xie, CL | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Zhang, Y | 1 |
| Zhang, SF | 1 |
| Wang, XJ | 1 |
| Liu, ZG | 1 |
| Carta, AR | 2 |
| Frau, L | 2 |
| Pinna, A | 2 |
| Morelli, M | 2 |
| Fisone, G | 2 |
| Aubert, I | 1 |
| Guigoni, C | 1 |
| Håkansson, K | 1 |
| Li, Q | 1 |
| Dovero, S | 1 |
| Barthe, N | 1 |
| Bioulac, BH | 1 |
| Gross, CE | 2 |
| Bloch, B | 1 |
| Bezard, E | 2 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Rosengarten, H | 4 |
| Bartoszyk, GD | 1 |
| Quartermain, D | 1 |
| Lin, Y | 1 |
| Tomiyama, K | 1 |
| Makihara, Y | 1 |
| Yamamoto, H | 1 |
| O'Sullivan, G | 1 |
| Nally, RE | 1 |
| Tighe, O | 1 |
| Kinsella, A | 1 |
| Fienberg, AA | 1 |
| Grandy, DK | 1 |
| Sibley, DR | 1 |
| Croke, DT | 1 |
| Koshikawa, N | 2 |
| Waddington, JL | 1 |
| Zhang, H | 1 |
| Ma, L | 1 |
| Wang, F | 1 |
| Chen, J | 1 |
| Zhen, X | 1 |
| Lucia, F | 1 |
| Annalisa, P | 1 |
| Pontis, S | 1 |
| Silvia, P | 1 |
| Simola, N | 1 |
| Nicola, S | 1 |
| Schintu, N | 1 |
| Nicoletta, S | 1 |
| Micaela, M | 1 |
| Schweitzer, JW | 3 |
| Friedhoff, AJ | 3 |
| LaHoste, GJ | 1 |
| Marshall, JF | 1 |
| Glenthøj, B | 2 |
| Kaur, S | 1 |
| Starr, MS | 1 |
| Starr, BS | 1 |
| Storey, E | 1 |
| Cipolloni, PB | 1 |
| Ferrante, RJ | 1 |
| Kowall, NW | 1 |
| Beal, MF | 1 |
| Bolwig, TG | 1 |
| Hemmingsen, R | 1 |
| Ohno, Y | 1 |
| Ishida-Tokuda, K | 1 |
| Ishibashi, T | 1 |
| Nakamura, M | 1 |
| Neal-Beliveau, BS | 1 |
| Joyce, JN | 1 |
| Ikeda, H | 1 |
| Adachi, K | 1 |
| Hasegawa, M | 1 |
| Sato, M | 1 |
| Hirose, N | 1 |
| Cools, AR | 2 |
| Canales, JJ | 1 |
| Iversen, SD | 3 |
| Van Kampen, JM | 1 |
| Stoessl, AJ | 1 |
| Boraud, T | 1 |
| Bioulac, B | 1 |
| Naidu, PS | 1 |
| Kulkarni, SK | 1 |
| Peacock, L | 2 |
| Gerlach, J | 4 |
| Van De Witte, SV | 1 |
| Groenewegen, HJ | 1 |
| Voorn, P | 1 |
| Diana, M | 1 |
| Collu, M | 1 |
| Mura, A | 1 |
| Gessa, GL | 1 |
| Lublin, H | 2 |
| Caporali, MG | 1 |
| Scotti de Carolis, A | 1 |
| Popoli, P | 1 |
| Spooren, WP | 1 |
| Piosik, PA | 1 |
| Neisewander, JL | 1 |
| Lucki, I | 1 |
| McGonigle, P | 1 |
| Rupniak, NM | 2 |
| Tye, SJ | 1 |
| Boyce, S | 1 |
| Steventon, MJ | 1 |
| Braun, A | 2 |
| Mouradian, MM | 2 |
| Mohr, E | 1 |
| Fabbrini, G | 2 |
| Chase, TN | 2 |
| Bédard, PJ | 2 |
| Boucher, R | 2 |
| Tamminga, CA | 1 |
| Egawa, M | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Di Paolo, T | 1 |
| Johansson, P | 1 |
| Levin, E | 1 |
| Gunne, L | 1 |
| Ellison, G | 1 |
| Kistrup, K | 1 |
| Korsgaard, S | 1 |
| Gerhardt, S | 1 |
| Gerber, R | 1 |
| Liebman, JM | 1 |
1 trial available for sk&f-38393 and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Basal Ganglia Diseases; Ben | 1989 |
47 other studies available for sk&f-38393 and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2020 |
Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzimida | 2021 |
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agent | 2018 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral | 2014 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; | 2013 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatu | 2015 |
Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Corpus Striatum; | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Ki | 2016 |
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
Monitoring dyskinesia with Zif.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Biomarker | 2010 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Behavior, | 2006 |
Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Chromans; Dopamine and cAMP-Reg | 2006 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease M | 2007 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Induction of oral dyskinesias in naive rats by D1 stimulation.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Dysk | 1983 |
Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dopamine Agoni | 1994 |
Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Apomorphi | 1993 |
Possible genetic factors underlying the pathophysiology of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphi | 1994 |
Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dizocilpine Maleat | 1994 |
Movement disorder following excitotoxin lesions in primates.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dyskinesia, Drug-I | 1994 |
Effects of chronic discontinuous and continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756).
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Benzofurans; Dopa | 1993 |
Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Avoidance | 1997 |
Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, | 1998 |
Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1999 |
Dynamic dopamine receptor interactions in the core and shell of nucleus accumbens differentially coordinate the expression of unconditioned motor behaviors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzopyrans; | 2000 |
Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Behavior, | 2000 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2001 |
Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Anticonvulsants; Antipsychotic | 2000 |
Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Arousal; Behavior, Animal; Cebu | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocil | 2002 |
Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; Animals; Antipsych | 1992 |
Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1992 |
N-ethyl-carboxamide adenosine inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Adenosine-5'-(N-ethylcarboxam | 1992 |
Dopamine D1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesia in cats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Cats; Dyskinesia, | 1991 |
Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain; Caudat | 1991 |
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Disease M | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Benzazepines; Dyskinesia, Drug-Induced; | 1988 |
Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Disease Models, A | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1988 |
Opposite effects of a D1 and a D2 agonist on oral movements in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dyskinesia, Drug- | 1987 |
Effect of selective D1 and D2 dopamine receptor antagonists and agonists in Cebus monkeys: implications for acute and tardive dyskinesias. A preliminary report.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acute Disease; Animals; Benzazepines; Bi | 1987 |
SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Benz | 1985 |